Hansen Medical, Inc. (HNSN) Stock Jumps 35% on FDA Clearance of Robotic Catheter eKit

Share

Investors of Hansen Medical, Inc. (NASDAQ:HNSN) are quite pleased this morning after the company announced that their Magellan(TM) Robotic Catheter eKit has received clearance from the U.S. Food and Drug Administration (FDA). While many were expecting clearance of the eKits, this certainly comes as good news, after months of speculation. The news has sent the stock soaring in morning trading

The eKits allow for doctors to control 3rd party microcatheters robotically through current Megellan Robotic Catheter 6Fr architecture. The goal of the kits are to help reduce exposure time to radiation and overall procedure time.

“We are proud to continue to offer advances in our portfolio of robotic catheters,” said Cary Vance, Chief Executive Officer of Hansen Medical. “We have seen strong robotic procedure growth, particularly in men’s health, women’s health and cancer treatment, since the introduction of the Magellan Robotic Catheter 6Fr, and we expect that the development of the Magellan Robotic Catheter eKit will continue to expand our presence within the Interventional Radiology space. We have placed a heavy focus on advancing our Magellan technology to enable robotic control of smaller catheters and look forward to the benefits that these added robotic capabilities will offer to patients and physicians.”

The stock is up 35.94% or $1.15 following the news, hitting $4.35 per share. About 728,722 shares traded hands or up 759.19% from the average. HNSN has declined 64.44% since June 26, 2015 and is currently downtrending. It has underperformed the S&P500 by 56.73%.

Hansen Medical, Inc. is engaged in the development and marketing of medical devices. The company has a market cap of $57.99 million. The Firm develops, makes and sells medical robotics designed for accurate positioning, manipulation and stable control of catheters and catheter technologies. It currently has negative earnings. The Company’s technology is used in medical procedures that are reliant upon tools like guide wires, catheters, sheaths, balloons and stents.

#focuskw=’Hansen Medical, Inc. (NASDAQ:HNSN)’##metadesc=’Investors of Hansen Medical, Inc. (NASDAQ:HNSN) are quite pleased this morning after the company announced that their Magellan(TM) Robotic Catheter eKit has received clearance from the U.S. Food and Drug Administration (FDA). While many were expecting clearance of the eKits, this certainly comes as good news, after months of speculation. The news has sent the stock soaring in morning trading

The eKits allow for doctors to control 3rd party microcatheters robotically through current Megellan Robotic Catheter 6Fr architecture. The goal of the kits are to help reduce exposure time to radiation and overall procedure time.

“We are proud to continue to offer advances in our portfolio of robotic catheters,” said Cary Vance, Chief Executive Officer of Hansen Medical. “We have seen strong robotic procedure growth, particularly in men’s health, women’s health and cancer treatment, since the introduction of the Magellan Robotic Catheter 6Fr, and we expect that the development of the Magellan Robotic Catheter eKit will continue to expand our presence within the Interventional Radiology space. We have placed a heavy focus on advancing our Magellan technology to enable robotic control of smaller catheters and look forward to the benefits that these added robotic capabilities will offer to patients and physicians.”

‘##metarobot=’index’##newskw=’Hansen Medical, Inc. news,Hansen Medical, Inc. – (NASDAQ:HNSN),NASDAQ:HNSN Analyst rating analysis,Stock Analysis,Outlook and potential,HNSN Price change and trend,HNSN stock update’##sitemap=’include’##skipsocial##stockticker=’NASDAQ:HNSN’#

COMMENTS: